Skip to main content
Clinical Trials/NCT05727540
NCT05727540
Recruiting
Not Applicable

The Cohort Study of Uveitis Patients Based on Real-world Data

Zhongshan Ophthalmic Center, Sun Yat-sen University1 site in 1 country600 target enrollmentFebruary 20, 2023
ConditionsUveitis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Uveitis
Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Enrollment
600
Locations
1
Primary Endpoint
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.

Registry
clinicaltrials.gov
Start Date
February 20, 2023
End Date
March 31, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • The diagnosis is uveitis; The agreement of enrolling this study;

Exclusion Criteria

  • Uveitis during the first month after any intraocular surgery; \<18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.

Outcomes

Primary Outcomes

The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

Time Frame: 12 months post-treatment

activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

Time Frame: 12 months post-treatment

inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

Secondary Outcomes

  • The number of intraocular pressure(6 months post-treatment)
  • The number of Intraocular pressure(36 months post-treatment)
  • Central retinal thickness(36 months post-treatment)
  • The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions(36 months post-treatment)
  • Best corrected visual acuity(36 months post-treatment)
  • The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system(36 months post-treatment)

Study Sites (1)

Loading locations...

Similar Trials